Seminar on Vinpocetine

Introduction The loss of cognitive functioning has become a major health concern due to the high number of individuals experiencing dementia, memory loss and other such difficulties, and also due to the lack of effective existing medical treatment. It is often passed off as a natural part of aging, but you will see that nutritional and botanical support are proven to enhance cognitive function and very importantly, help reverse and prevent cognitive dysfunction. We will be discussing the botanical extract Vinpocetine. Background At birth the human brain contains as many as one hundred billion nerve cells. From then on there is a continuous process of decline. Brain weight decreases gradually over time - about 10% over a normal life span, due to neuron death. Different parts of the brain lose neurons at different rates. In most brain stem regions below the cerebral cortex (the area responsible for automatic unlearned activity (breathing, heart pumping, blinking, etc.), there is little or no cell loss with advancing age. In comparison, the cerebral cortex, which is responsible for thinking and memory, loses up to 50,000 neurons a day. Definition/Description Vinpocetine is a derivative of Vincamine, which is an alkaloid of the common periwinkle plant (Vinca minor). It selectively dilates the arteries and capillaries in the head area, which improves circulation to the brain, thus alleviating cerebral insufficiency. Ongoing research around the world indicates that it may help improve memory, learning ability, insomnia, hearing, eyesight, and effects of menopause, and increase tolerance to damage caused by hypoxia (lack of oxygen, such as occurs with a stroke or heart attack). Vinpocetine is often used for the treatment of cerebral circulatory disorders such as memory problems, acute stroke, aphasia (loss of the power of expression), apraxia (inability to coordinate movements), motor disorders, dizziness, tinnitus and other inner-ear problems, and headache. Vinpocetine is also used to treat acute or chronic

sleep disorders. Speeds up the use of glucose in the brain. Speeds up the use of oxygen in the brain. 3. 5. the improvement of blood flow to the brain. (Kiss. (Shibuya) . as it is immediate and practical to measure. (Luciana) Acetylcholine: Associated with memory and memory loss. with visual acuity improving in 70% of the subjects. addiction disorders. Dopamine: Associated with reward-seeking behaviour and spatial working memory tasks. In particular. Miyata) 5 ways Vinpocetine increases brain metabolism: 1. Increases the rate at which brain cells produce ATP (which is a cell molecule that creates energy). appetite disorders. (Milusheva. Many studies have been performed on cerebral metabolism. Regulates Sodium/ Potassium channels 4. etc. Vinpocetine increases levels of neurotransmitters involved in memory function: Noradrenaline: Found principally in neurons of the locus coeruleus (LC) area of the brain. How Vinpocetine Effects the Brain Vinpocetine improves four different and fundamental aspects of cerebral metabolism. 2. It is important to note that Vinpocetine is not only a cerebral vasodilator. but that its principal action is a beneficial effect on the cerebral metabolism. Matsukawa) Serotonine: Associated with mood regulation and sleep.ophthalmological diseases of various origins. Increases blood flow. Low levels have been associated with depression.

The final result of the joint actions is the improvement of overall cognitive function. on induced impairment of memory were studied in eight normal volunteers. Vinpocetine has several different effects that have various important effects on cognitive function. (Subhan) The effects of pre-treatment with vinpocetine 40 mg. show that Vinpocetine increases the firing ability on LC and therefore improve cognition and related cognitive-enhancing characteristics. This decline plays a significant role in the reduction of concentration. sleep-wake cycle. normal. anxiety. This treatment with vinpocetine was also associated with improvements in short-term memory processes. Of vinpocetine. healthy volunteers showed incredible short-term memory improvement one hour after taking 40 mg. vinpocetine improves overall cerebral efficiency resulting in brain cells that can better retain information so we can remember more. (Vamposi) Vinpocetine increases ATP synthesis (Nicholson) and is especially beneficial for individuals whose dementia may be caused by vascular insufficiency. LC neurons decline in number with age . These result in benefits for: Dementia Both animal and human studies show Vinpocetine is able to restore impaired brain energy metabolism. By acting in these five ways. stress and autonomic control.Vinpocetine stimulates Locus Coeruleus (LC) neurons: LC Neurons are the noradrenaline nerve clusters throughout the cerebral cortex of the brain.degeneration is slightly faster in men compared to women. alertness and information processing associated with aging. (Bhatti) . These are involved in regulating learning and memory. et al. (Biro) Short term memory and learning In one double-blind crossover study. Animal studies conducted in Hungary by Gaal.

Stroke Vinpocetine also has properties as an anti-platelet aggregation blood thinner. (Ravecca) Tinnitus is one of the problems for which vinpocetine has been most studied and results are very promising. This inhibits blood clotting and aids in the normalization of blood flow. which can be useful for treatment of stroke and aid in the reflow of blood to these areas. Konopke. have studied its specific action on memory. Vinpocetine selectively dilates the cerebral artery. Ribari. which are all inner ear disorders of vascular origin. Ordogh. and other vision disorders of vascular origin. The increase of blood viscosity and/or increase of rigidity of the red blood cells have been reported by several authors as a contributing factor. Over more than 100 clinical trials have been performed with vinpocetine. and some of them. .000 patients. certain problems related to glaucoma.Studies have also shown memory improvement in the elderly. (Taiji. as well as its general action of vinpocetine in the brain. on a total of over 20. Vision Problems Vinpocetine has been used for blood flow problems of the choroid and retina. Matsnev) Vascular problems of the inner ear such as tinnitus can benefit from vinpocetine as it has been used for the hearing loss of senile or toxic origin and labyrinthic vertigos (dizziness). The majority of these studies were performed with elderly patients. such as macular degeneration. Other Applications Tinnitus and Other Hearing Problems Hearing dysfunction such as tinnitus (ringing in the ears) and progressive sensorineural hearing loss (PSNHL) are commonly caused by cerebral vascular factors.

The also study suggested the involvement of a prostaglandin-mediated mechanism against acetic acid-induced damage. researchers noted vinpocetine’s inhibition of platelet aggregation (clotting). Blood levels of alkaline phosphatase and bone osteocalcin tended to decrease after treatment with vinpocetine. among other factors. . The effectiveness of vinpocetine to prevent gastric mucosal damage induced by several agents and its antisecretory effect was studied in rats. The microvessels that feed neurons in the brain and retina are smaller in diameter than a single red blood cell and are easily “clogged” by clumps of platelets. Vinpocetine proved to inhibit the development of gastric lesions induced by 96% ethanol in a dose-dependent way. which may be triggered by a high fat diet. The highest protective activity was observed when vinpocetine was given 30 minutes before ethanol. researchers suspected that it may be of benefit to remove undesirable mineral deposits elsewhere in the body as well. As other studies have shown that vinpocetine can effectively scavenge undesirable minerals and/or metals in the soft tissues of rabbits with artificially induced arteriosclerosis. Histamine-stimulated gastric acid secretion was partially inhibited by vinpocetine. This provides another mechanism of action for vinpocetine’s ability to enhance cerebral blood flow-inhibition of unnecessary platelet aggregation. and its effect was still significant when administered 120 minutes before ethanol exposure. (Kaham) Stomach Ulcers Vinpocetine may help ward off stomach ulcers./day for 3-12 months. (Nosalova) Kidney Stones Japanese researchers at the Wakayama Medical College showed that vinpocetine supplementation is able to remove tumoral calcinosis in kidney dialysis patients with renal (kidney) failure. impairing microcirculation. kidney dialysis patients with X-ray evidence of kidney stones (tumoral calcinosis) experienced complete elimination of calcinosis in all eight cases. and stress hormones. In the Japanese study.In a study with 100 patients suffering from poor blood circulation to the eye. after vinpocetine administration of 15 mg. magnesium deficiency.

The most common ingredient used against hair loss is Mynoxidil. some people taking vinpocetine orally. stating they no longer feel strong hair loss. (Covex) Studies are being performed with hydroalcoholic solutions of vinpocetine. which is a strong peripheral vasodilator with adverse side effects.Vinpocetine had this remarkable effect without any side effects during treatment. have reported are more vigorous hair condition. (Miyata) Hair Loss Due to the improvement of peripheral microcirculation in microvessels of the head. The mechanism of action of Vinpocetine is the same but with the advantage of no side effects. used as hair lotions for the hair skin. (Covex) .

also vinpocetine’s effects are much quicker .Commonly Asked Questions about Vinpocetine Q: How is Vinpocetine different from Ginkgo Biloba? A: Ginkgo’s main effects on cerebral vascular functions are mainly due to its vasoactive and antioxidant effects. others may not see major improvement in medical situations for weeks or months. with tinnitus and dizziness improving somewhat later. A minimum of 4 to 6 weeks were needed before a pronounced effect could be expected. . This means there is actually a reduction in the effort of the heart. systemic circulation and actually vascular resistance actually slightly decreases. it is increasing the heart rate and how does this affect the heart? A: Vinpocetine selectively increases the cerebral fraction of cardiac output.many individuals experiencing benefit in just a few days. It does not effect blood pressure. Vinpocetine seems to have a much broader mode of action and can therefore assist a wider variety of individuals . Q: If Vinpocetine increases blood flow to the brain. (Solti) Q: How long does it take to see any results when taking Vinpocetine? A: While some Vinpocetine users notice cognitive improvements after a single dose or within the first few days. Studies involving 1. concentration. (Soholm) It’s active terpenes are antagonists of PAF (Platelet activating factor) which has negative neural effects. Improvements in cerebral disorders and in hearing and vision problems may last only as long as it is being taken on a regular basis. and alertness were the first symptoms to be relieved by use of Ginkgo Biloba.200 patients showed that memory.

These will discontinue if you reduce your dosage or stop taking it. Q: Can Vinpocetine be used with other supplements? A: Vinpocetine works great taken alone. It is best to take Vinpocetine with food to avoid stomach upset.. Q: Are there any side effects with Vinpocetine? A: Vinpocetine is very safe for long-term use. Vinpocetine is normally taken orally. Q: What happens if you take too much? A: The most commonly reported feeling is a sensation of feeling over-revved. If taken with other cerebro-active substances. and yet also works well when combined with other memory enhancing nutrients. It may interfere with sleep so I would not suggest taking a high dosage in the evening. Other mild side effects reports include dry mouth. rapid heartbeat. . two or three times daily.Q: What is the suggested dosage? A: The usual therapeutic dose for Vinpocetine for humans is 15-30 mg. Vinpocetine may enhance their effects thus possibly reducing their dosage requirements. per day. low blood pressure and rash/or hives. 5-10 mg.

. Canada. Bukanova I. Gelpke LW. Covex. Hungary. Spain.9 Suppl 4:41-5 Bhatti JZ. 28. Wood LM. Solntseva E. University of Leeds.4(2):35776. University of Western Ontario. Int Clin Psychopharmacol 1995 Jan. DeNoble VJ.24(4):1123-8. Nootropic agent vinpocetine blocks delayed rectified potassium currents more strongly than high-threshold calcium currents. Science Research Institute of the Brain.28(2):116-20.92(1):38-40. Vinpocetine: nootropic effects on scopolamine-induced and hypoxia. Zh Nevropatol Psikhiatr Im S S Korsakova. Solntseva E. Hungary. Human Psychopharmacology Research Unit. U.. Repetti SJ. Middlesex.46(5):911-6. Russian Academy. Southall. Eur J Pharmacol 1996 Oct 24. Baillieres Clin Neurol 1995 Aug. Vinpocetine enhances retrieval of a step-through passive avoidance response in rats. Lakics V. Moscow. et al. 1918-20.K. Molnar P. Ealing Mental Health Unit. personal conversation 11/16/99. Madrid. Keim KL. UK. 1992.induced retrieval deficits of a step-through passive avoidance response in rats. Gafurov BG. Biochem Behav 1987 Jan.314(1-2):69-73.2(4):325-31. Bowler J. Bukanova Y. “Protective activity of Ethyl Apovincaminate on ischaemic anoxia of the brain” AF(DR) 1976. Department of Biochemistry. DeNoble V. London. Biro. Medical Sciences. [The nootropic agent vinpocetine blocks the delayed rectifier potassium channel more strongly than the high-conductance calcium channel] Zh Vyssh Nerv Deiat Im I P Pavlova 1996 Sep-Oct.. K. Effect of vinpocetine on noradrenergic neurons in rat locus coeruleus. Int Clin Psychopharmacol 1987 Oct. Erdo SA. .187(3):537-9. Vinpocetine effects on cognitive impairments produced by flunitrazepam.Bibliography Baldwin D. Vascular cognitive impairment: a new approach to vascular dementia. Budapest. Laboratory of CNS Pharmacology. Neurosci Behav Physiol 1998 Mar-Apr. Hindmarch I. Hachinski V. Tomoskozi Z.Budapest. Vincamine and vincanol are potent blockers of voltage-gated Na+ channels. Molnar P. Gaal L. Rudge S. Pharmacol Biochem Behav 1986 Apr. Eur J Pharmacol 1990 Oct 23. Bence JZ. The role of serotonine in depression and anxiety. Chemical Works of Gedeon Richter Ltd. Chinoin Co. Status of the nonspecific systems of the brain in initial manifestations of insufficiency of cerebral blood supply and circulatory encephalopathy. Busakov BS.26(1):183-6.

et al. Ltd. Karpati E. Collins PF. L.51:219-44. 14: 577.. Ibaraki. U of Oregon.. Eli Lilly and Company. 55. El Cerrito. Luciana M. Aviation. Tesco G. Taiji. Meiri N. Res.. Maeshima T. Cereb Cortex 1998 Apr-May. Fornal CA. Serotonin and acetylcholine are crucial to maintain hippocampal synapses and memory acquisition in rats.4(3):144-61. Altern Medical Rev 1999 Jun. Serotonine in migraine: theories. CA 94530. F.. Matsukawa M. Nebreda. Johnson KW.. H. 263-279. USA. Kiss. hatasmechanizmusa. Bethesda. Szporny. 1986. A.. Bodo.Garcia. Phebus LA. On the possible role of central monominergic systems in the central nervous systems actions of vinpocetine. Perlado. Kiss B.4:281-6. MD. E. Institute of Basic Medical Sciences. Department of Psychology. Activity of serotonergic neurons in behaving animals.. Opposing roles for dopamine and serotonin in the modulation of human spatial working memory functions. Galeotti N. Chinoin Co. Space and Enviromental Medicine. D.230(1):13-6 Matsnev. Farmakologiai Kutato Kozpont. Use of Ethyl Apovincaminate in ophthalmological therapy” AF(DR) 1976.21(2 Suppl):9S15S. Reversible ntisense inhibition of Shakerlike Kv1.”...Vinpocetine is a highly potent neuroprotectant against veratridine. [Mechanism of action of vinpocetine] Vinpocetine hatasai.. “Experimental Assessment of Selected Antimotion Drugs”. Budapest. 9. University of Tsukuba. D of Psychology. A review of nutrients and botanicals in the integrative management of cognitive dysfunction Contributing Editor. Ghelardini C. Jacobs BL.94(9):4430-4. 1994. Drug Dev. Ogawa M.induced cell death in primary cultures of rat cerebral cortex. 8(3):218-26. Eugene. CNS Pharmacology Laboratory. . Neurosci Lett 1995 Feb 9. Erdo SL. Budapest.. Richter Gedeon Vegyeszeti Gyar Rt. Lilly Corporate Center. Indianapolis. “Clinical Study of Vinpocetine in the treatment of vertigo. Nakadate K. Kaham. 1984. 28. Kawai N. et al.. Lilly Research Laboratories. L. Neurosci Lett 1997 Jul 11.. Mental Illness in the Elderly. Hungary. J. Correspondence address:47 Elm St. Sebestyen MG.. JPN Pharmacol Ter. Dahl D. IN Prog Drug Res 1998. Alternative Medicine Review. animal models and emerging therapies. Japan. Kanzaki. National Institutes of Health. Lakics V.66(5):213-24.1 potassium channel expression impairs associative memory in mouse and rat. B. (1988) 14. Cohen ML. 0. OlahM. NJ. Kidd PM. Proc Natl Acad Sci U S A 1997 Apr 29.185(2):127-30. 1969-72.Acta Pharm Hung 1996 Sep. Ichitani Y. Neuropsychopharmacology 1999 Aug. Princeton University.

Japan. Srossy. Toth G.related impairment evidence in electroencephalograph.1:16-9. C. Pharmacology of nootropics and metabolically active compounds in relation to their use in dementia. “Therapeutic Action of Cavinton in Hearing Defects of Neurological Origin”. Machova J. Ltd. Karpati E. Alzheimer’s Disease Research Center. Szantay C.. Effects of VA-045. Nosalova V. Saitama. Synthesis of vinca alkaloids and related compounds. D. 1985. Temesvari-Major E. Chinoin Co.. Erdo SL. Bull. Kawashima Y. Psychopharm. B.Meltzer CC.Effects of VA-045. Research Center. Inhibitory effect of hypoxic condition on acetylcholine release is partly due to the effect of adenosine released from the tissue. 26. Goteborg University. Milusheva. Eriksson P. University of Pittsburgh Medical Center. Slovak Academy of Sciences. Szporny. Sperlagh.273(3):303-6.147-59.. Life Science. B. Yamaura H. a novel apovincaminic acid derivative. Enriched environment increases neurogenesis in the adult rat dentate gyrus and improves spatial memory.39(4):569-78. Arzneimittelforschung 1993 Sep. Serotonin in aging. Smith G. . Eur J Pharmacol 1995 Feb 6. 1978 . 369-373. Muramatsu M.18(6):407-30. Okuyama S. Ogawa S. Szantay C Jr. Bratislava.. et al. Miyazaki M.25(7): 1311-20 Ordogh. J Neurobiol 1999 Jun 15. Araki H. (1990).. B. 1997 Jun. et al. Nicholson. on isolated blood vessels: cerebroarterial selectivity.. Tanaka M. a novel apovincaminic acid derivative. Johansson U. et al. Pollock BG.et al. Institute of Clinical Neuroscience. Babulova A. DeKosky ST. 101. Hungary.. Otomo S. on age. Gen Pharmacol 1994 Nov. a passive avoidance task and cerebral blood flow in rats. Brain Res.. and Alzheimer’s disease: the emerging role of functional imaging. Sulfonamide derivatives of some vinca alkaloids with cardiovascular activity. Kawashima K. 24. vinpocetine. Sahlgrenska University Hospital. Protective action of vinpocetine against experimentally induced gastric damage in rats. Ltd. Taisho Pharmaceutical Co.. Budapest.46(1): 53-8. Kiss. Sweden. Therapia Hungarica. late-life depression. CNS Pharmacology Laboratory. Imagawa Y. Part 84.. E. Angiology 1995 Jan.43(9):981-5. Molnar P. Institute of Experimental Pharmacology. Tsuchida K. caudate spindle.330(6):190-8. The effect of a cerebral vasodilator. Perfilieva E. PA Neuropsychopharmacology 1998 Jun. Nilsson M. Moldvai I. Miyata N. Hashimoto-Kitsukawa S. L. Vinpocetine is as potent as phenytoin to block voltage-gated Na+ channels in rat cortical neurons. on cerebral vascular resistance evaluated by the Doppler ultrasonic technique in patients with cerebrovascular diseases. Orwar O.

Solntseva EI. UK. Finland. Adv Ther 1998 JanFeb. Soholm B. (1986) 38.. K. Partanen J. Sinclair AJ. Soininen H. Neuroscience. Hungary. E. 1945-47. et al.84(8):741-6. Vedbaek. Igaku No Ayumi (1986) 139. Eur J Drug Metab Pharmacokinet 1993 Oct-Dec.16(3):419-24. Neuroscience 1999. Relationship between EEG reactivity and neuropsychological tests in vascular dementia. et al. Budapest. J Neural Transm 1997.. Moscow. histological study of brain monomines. Bayer AJ. University of Virginia. Solti. Altered plasma antioxidant status in subjects with Alzheimer’s disease and vascular dementia. Nicholson GM. 811-21.) 1976.93(2):557-63. Russia. 28.a valuable tool in testing the antioxidative activity of amphiphilic drugs stobadine and vinpocetine.89(4):1135-43. et al “Comparison of vinpocetine with Ifenprodil Tartrate and Dihyroergotoxine Mesylate treatment and results of long term treatment with vinpocetine. et al.” Curr Ther Res (1985) 37.104(8-9):905-12. Clinical improvement of memory and other cognitive functions by Ginkgo Biloba: review of relevant literature. Bukanova IuV. Stefani MR. 1977. Stancikova M. (3H) Noradrenaline-releasing action of vinpocetine in the isolated main pulmonary artery of the rabbit. T. Denmark. J Pharm. et al. et al. Pudleiner P. 1999. [Cyclic GMP mimicks potentiation effect of the nootropic agent vinpocetine on the high threshold A-current in the mollusk neurons] Institute of Brain Research. “Effect of Ethyl Apovincaminate on the cerebral circulation” AF(DR) 1976. (Drug. Kononen M. Otomo. 3. University Hospital of Kuopio. Study on the absorption of vinpocetine and apovincaminic acid. Charlottesville. 10. T. Gold PE. et al.. Shibuya.T. Res. Birmingham. Pharmaacol.13(12):840-5. Ribari. “Ethyl Apovincaminate in the Treatment of Sensorineural Impairment of hearing. Department of Psychology.15(1):54-65. P. Sato. F.-Forsh. Effects of vinpocetine on experimental brain ischemia. Toth. 668-673. Ross Fiziol Zh Im I M Sechenova 1998 Aug. Sano-Pharm A/S. ATP-sensitive potassium channel blockade enhances spontaneous alternation performance in the rat: a potential mechanism for glucose. Soltes L. 217-219. Paulo. . Stancampiano R. Int J Geriatr Psychiatry 1998 Dec.mediated memory enhancement.” Arzneim. Chemical Works of Gedeon Richter Ltd. Vereczkey L. Selly Oak Hospital. Helkala EL.18(4):317-21. J Pharm Biomed Anal 1997 Nov.Orvisky E. High-molecular-weight hyaluronan. Serotonin and acetylcholine release response in the rat hippocampus during a spatial memory task.

drowsiness. appraisal of vinpocetine for the removal of intractable tumoral calcinosis in haemodialysis patients with renal failure. Marder E.8(4):197-204. Cerebral effects of a single dose of intravenous vinpocetine in chronic stroke patients: a PET study. Japan. School of Basic Medical Sciences.75(2):963-6. Yamaguchi K. Tagawa K. 26(6): 1419-24. The neuroprotective drug vinpocetine prevents veratridine-induced [Na+]i and [Ca2+]i rise in synaptosomes. Abbott LF.20(5):435-43. Cellular short-term memory from a slow potassium conductance. et al (1976) “Comparative study of the effect of Ethyl Apovincaminate and Xanthinol Nicotinate in cerebrovascular diseases” Arzneim Forsch (drug research) 28. Adam-Vizi V. Vamosi. Waltham. .18(5):411-5. epinephrine and gammaaminobutyric acid inhibitory actions in the rat locus coeruleus.et al. Effect of vinpocetine on oxygen release of haemoglobin and erythrocyte organic polyphosphate concentrations in patients with vascular dementia of the Binswanger type. Chiba K. Eur J Clin Pharmacol 1985.40(6):640-3. Semmelweis University of Medicine. Psychopharmacological effects of vinpocetine in normal healthy volunteers. Balkay L. Department of Neurology. Japan. Department of Biology. Wei Y. Zhong CS. Hungary.9(8):1849-53. Neuroreport 1998 Jun 1. Tohgi H. Debrecen University Medical School. 1980-84. Shi NC. Gen Pharmacol 1995 Oct. and a lack of drive as major symptoms] Fukuoka Higher Bain Function Center.. Okuyama S. Inhibitory effects of vinpocetine on sodium current in rat cardiomyocytes.Effects of VA-045 on peripheral and central circulation in anesthetized dogs.89(11):303-11. Brandeis University. Nihon Bioresearch Center Inc.47(1):1-15. Tretter L. Iwate Medical University. Ota K. Boros I. Ueyoshi A. Szakall S. J Neurophysiol 1996 Feb.) Van Bockstaele EJ. Cerebrovascular disorder with memory disturbance.28(5):567-71. Brain Res Bull 1998 Sep 1. Turrigiano GG. Ma. Yamada S. Department of Medical Biochemistry. Hungary. Budapest. Chung Kuo Yao Li Hsueh Pao 1997 Sep. J Int Medical Res 1992 Sep. Shanghai Medical University. Gifu. Sasaki K. Hindmarch I. B. Emri M. et al. J Neuroimaging 1998 Oct. China. Morphological substrates underlying opioid. Arzneimittelforschung 1990 Jun. Nagao Hospital 814-0153 Fukuoka Igaku Zasshi 1998 Nov. Nozaki Y.Subhan Z.

Sign up to vote on this title
UsefulNot useful